BACKGROUND A syndromic gastrointestinal pathogen panel (GIP) was implemented in May 2018. All positive (+) GIP and standard-of-care (SOC) C. difficile results were reviewed. METHODS A single-center audit of adult patients with GIP results was conducted May-December 2018. We reviewed GIP(+)/SOC(+/-) and GIP(-)/SOC(-) tests (control group) for clinical outcomes. RESULTS We reviewed 269 GIP(+) patients. Of 119 GIP(+)/SOC(+) patients, 44 (37%) were positive by toxin A/B enzyme immunoassay, and 75 (63%) by PCR only. Thirty-day mortality and re-admission were not significantly different between groups. CDI rates within 6 months were not significantly different between GIP(+)/SOC(-) and controls (p-value = 0.39). Those with initial SOC(+) tests had more true CDI events within 6 months, compared to controls (p-values < 0.001). CONCLUSIONS Forty percent of patients with GIP(+) C. difficile were (-) by SOC test, suggesting that true CDI was not present. Additional PCR-based testing may not impact outcomes.

中文翻译：

---

难辨梭状芽孢杆菌聚合酶链反应的诊断工作是由症状性腹泻组及其对患者预后的影响所致。

背景技术胃肠道病原体综合症专家组（GIP）于2018年5月实施。对所有阳性（+）GIP和护理标准（SOC）艰难梭菌结果进行了审查。方法2018年5月至12月对成年患者的GIP结果进行了单中心审核。我们对GIP（+）/ SOC（+/-）和GIP（-）/ SOC（-）测试（对照组）的临床结局进行了回顾。结果我们审查了269名GIP（+）患者。在119名GIP（+）/ SOC（+）患者中，毒素A / B酶免疫法阳性44例（37％），仅PCR阳性75例（63％）。两组之间的30天死亡率和再次入院没有显着差异。GIP（+）/ SOC（-）与对照组之间的6个月内CDI率无显着差异（p值= 0.39）。与对照组相比，那些进行了初始SOC（+）测试的患者在6个月内有更多的真实CDI事件发生（p值<0.001）。结论通过SOC测试，有40％的GIP（+）艰难梭菌患者为（-），表明不存在真正的CDI。其他基于PCR的测试可能不会影响结果。